JP2022540384A5 - - Google Patents

Info

Publication number
JP2022540384A5
JP2022540384A5 JP2021578267A JP2021578267A JP2022540384A5 JP 2022540384 A5 JP2022540384 A5 JP 2022540384A5 JP 2021578267 A JP2021578267 A JP 2021578267A JP 2021578267 A JP2021578267 A JP 2021578267A JP 2022540384 A5 JP2022540384 A5 JP 2022540384A5
Authority
JP
Japan
Prior art keywords
seq
sequence shown
nos
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021578267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540384A (ja
JP7678768B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050689 external-priority patent/WO2021000017A1/en
Publication of JP2022540384A publication Critical patent/JP2022540384A/ja
Publication of JP2022540384A5 publication Critical patent/JP2022540384A5/ja
Priority to JP2025003471A priority Critical patent/JP2025077045A/ja
Application granted granted Critical
Publication of JP7678768B2 publication Critical patent/JP7678768B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021578267A 2019-07-02 2020-07-02 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 Active JP7678768B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025003471A JP2025077045A (ja) 2019-07-02 2025-01-09 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902343 2019-07-02
AU2019902343A AU2019902343A0 (en) 2019-07-02 Antibodies
PCT/AU2020/050689 WO2021000017A1 (en) 2019-07-02 2020-07-02 Antibodies against caix with reduced affinity for the neonatal fc receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025003471A Division JP2025077045A (ja) 2019-07-02 2025-01-09 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体

Publications (3)

Publication Number Publication Date
JP2022540384A JP2022540384A (ja) 2022-09-15
JP2022540384A5 true JP2022540384A5 (enExample) 2023-07-10
JP7678768B2 JP7678768B2 (ja) 2025-05-16

Family

ID=74100150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578267A Active JP7678768B2 (ja) 2019-07-02 2020-07-02 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体
JP2025003471A Pending JP2025077045A (ja) 2019-07-02 2025-01-09 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025003471A Pending JP2025077045A (ja) 2019-07-02 2025-01-09 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体

Country Status (12)

Country Link
US (2) US20220331457A1 (enExample)
EP (1) EP3994176A4 (enExample)
JP (2) JP7678768B2 (enExample)
KR (1) KR20220057516A (enExample)
CN (1) CN114502596A (enExample)
BR (1) BR112021026651A2 (enExample)
CA (1) CA3141457A1 (enExample)
CL (2) CL2021003561A1 (enExample)
IL (1) IL289524A (enExample)
MA (1) MA56467A (enExample)
MX (1) MX2021015670A (enExample)
WO (1) WO2021000017A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4294845A4 (en) * 2021-02-22 2026-01-07 Abdera Therapeutics Inc Immunoconjugates for targeted radioisotope therapy
KR20240049818A (ko) * 2021-08-17 2024-04-17 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 병용 방사선요법
US20240359144A1 (en) * 2021-09-01 2024-10-31 Telix Pharmaceuticals (Innovations) Pty Ltd Aggregate separation method
EP4536296A1 (en) * 2022-06-09 2025-04-16 Telix Pharmaceuticals (Innovations) Pty Ltd Combination therapy
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
JP2026510493A (ja) * 2023-03-09 2026-04-07 テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド 多機能抗体
CN122270294A (zh) * 2023-12-01 2026-06-23 泰利斯制药(创新)有限公司 新型放射性标记抗体
TW202611088A (zh) 2024-07-23 2026-03-16 美商雅博得樂醫療公司 5t4結合多肽及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1358318T3 (da) * 2001-02-07 2007-01-02 Wilex Ag Hybridomcellelinje G250 og dens anvendelse til frembringelse af monoklonale antistoffer
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1979379B1 (en) * 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
WO2008091798A2 (en) * 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
MX2011012047A (es) * 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
CN102775500A (zh) * 2012-08-03 2012-11-14 郑骏年 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
TW201920285A (zh) 2013-04-29 2019-06-01 瑞士商赫孚孟拉羅股份公司 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途
CA2904806C (en) * 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CA2926215A1 (en) * 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
CN110903398B (zh) * 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
CN110981957B (zh) * 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
EP4086285A1 (en) * 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
EP3502139A1 (en) * 2017-12-19 2019-06-26 Philogen S.p.A. Antibodies to tumour antigens

Similar Documents

Publication Publication Date Title
JP2022540385A5 (enExample)
JP2025069166A5 (enExample)
JP7828375B2 (ja) 標的分子に対する抗原結合コンストラクト
JP2025077045A5 (enExample)
AU2018388467B2 (en) Radiolabeling of polypeptides
Reilly Monoclonal antibody and peptide-targeted radiotherapy of cancer
US11981741B2 (en) Humanized anti-CD45 antibodies
CA3141471A1 (en) Antibodies for binding psma with reduced affinity for the neonatal fc receptor
JP2009268470A (ja) 抗体分子を用いての腫瘍脈管系の選択的標的化
CA3205707A1 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
CA3141457A1 (en) Antibodies against caix with reduced affinity for the neonatal fc receptor
JP2025510189A5 (enExample)
JP2024532372A5 (enExample)
CN100482285C (zh) 放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管的制药用途
CA3180690A1 (en) Cd38 antibodies for treatment of human diseases
WO2024055040A2 (en) Humanized anti-cd45 antibodies
JP2023550462A5 (enExample)
CA3258344A1 (en) CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CA3208566A1 (en) Antibodies to igf2r and methods
ES2541907T3 (es) Secuencias de nucleótidos y proteínas de un anticuerpo dirigido frente a un epítopo común para ferritínas humanas ácidas y básicas, anticuerpos monoclonales o moléculas semejantes a anticuerpo que comprenden estas secuencias y uso de éstos.
JP2023518818A5 (enExample)
TH2401004071A (th) สารประกอบที่มุ่งเป้า EGFR-cMET และการใช้สิ่งดังกล่าว
HK40066936A (en) Antibodies against caix with reduced affinity for the neonatal fc receptor
AU2024335556A1 (en) Anti-nectin-4 antibodies and methods of use thereof
TW202607033A (zh) 抗ｒｏｒ２抗體－放射性核種結合物